More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.05B
EPS
0.16
P/E ratio
--
Price to sales
0.63
Dividend yield
--
Beta
1.28369
Previous close
$13.98
Today's open
$13.82
Day's range
$13.40 - $13.89
52 week range
$8.70 - $20.49
show more
CEO
Stuart Essig
Employees
4427
Headquarters
Princeton, NJ
Exchange
Nasdaq Global Select
Shares outstanding
77800976
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire • 20 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire • Nov 10, 2026

Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
Seeking Alpha • Nov 10, 2026

Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference
PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 2:45 p.m. ET.
GlobeNewsWire • Nov 6, 2026

Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological Surgeons (CNS) Annual Meeting, taking place October 31-November 4 in Washington, D.C. At this year's meeting, Integra will showcase its comprehensive neurosurgery portfolio through interactive educational experiences, hands-on training and technologies that support neurosurgeons across the continuum of care.
GlobeNewsWire • Oct 30, 2026

Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 2, 2026 disclosure c.
Business Wire • Oct 23, 2026

Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 2, 2026 disclosure regarding Integra.
Business Wire • Oct 23, 2026

Integra LifeSciences: Progress Remains Frustratingly Slow, But Valuation Is Getting Interesting
Integra LifeSciences remains pressured by operational challenges, but restructuring and a returning CEO offer renewed turnaround potential. IART's Wound Reconstruction business continues to underperform, though upcoming product relaunches and market normalization could drive recovery. Valuation appears undemanding, with EBITDA margin expected to exceed 20% in 2025 and double-digit FCF margins possible by 2028.
Seeking Alpha • Oct 23, 2026

Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Integra LifeSciences Holdings Corporation ("Integra" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Integra LifeSciences Holdings Corporation (NASDAQ: IART), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Integra LifeScience.
Business Wire • Oct 22, 2026

What Integra LifeSciences (IART) Said on Its Q3 Earnings Call
Integra LifeSciences NASDAQ: IART reported third-quarter revenue at the low end of its guidance range as a flooding-related disruption at its Cincinnati facility and slower-than-expected Tissue Reconstruction performance weighed on results. The company said strength in neurosurgery and international Specialty Surgery partially offset those pressures.
MarketBeat • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Integra LifeSciences Holdings Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.